Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study

被引：0
|
作者：
Vermersch, P.
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. Soelberg
Kurukulasuriya, N.
Viglietta, V.
Chang, P.
Papasouliotis, O.
Greenberg, S.
机构：
[1] Univ Lille Nord de France, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Univ Med & Dent, Newark, NJ USA
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Univ Miami, Miami, FL USA
[6] Univ Erlangen Nurnberg, Bamberg, Germany
[7] Copenhagen Univ Hosp, Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [1] Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study
    Vermersch, Patrick
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Kurukulasuriya, Nuwan C.
    Viglietta, Vissia
    Chang, Peter
    Papasouliotis, Orestis
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A246 - A247
  • [2] Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Bischof, D.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
  • [3] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
  • [4] Safety and Efficacy of Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis in Patients with High Disease Activity: Results from the Phase III, 96-Week CLARITY Study
    Rammohan, Kottil
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Kurukulasuriya, Nuwan C.
    Chang, Peter
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A612 - A613
  • [5] Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Vermersch, P.
    Bock, D.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S143
  • [6] Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Soelberg, Per
    Rieckmann, Peter
    comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Vermersch, Patrick
    Bock, Daena
    Hamlett, Anthony
    Fevr, Tea
    Musch, Bruno
    Greenberg, Steve
    NEUROLOGY, 2010, 74 (09) : A372 - A372
  • [7] Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 485 - 485
  • [8] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [9] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S21 - S21
  • [10] Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S20 - S20
12345